Metabolomics is an emerging technology that allows researchers to characterize hundreds of small molecules that comprise the metabolome. We sought to determine metabolic differences in depressed and nondepressed participants. The sample consisted of a depressed group of patients with heart failure enrolled in an NIMH-supported clinical trial of sertraline versus placebo in depressed heart failure patients, and a nondepressed comparator group of heart failure patients. Plasma was obtained from blood samples provided by participants at baseline, and samples were profiled on GC-MS and LC-MS metabolomics platforms for biochemical content. A number of biochemicals were significantly different between groups, with depressed participants showing higher concentrations of several amino acids and dicarboxylic fatty acids. These results are consistent with prior findings where changes in neurotransmitter systems and fatty acid metabolism were shown to associate with the depressed state. It is unclear what role heart failure may have played in these differing concentrations.
Introduction
Metabolomics tools enable us to study the metabolome, the repertoire of small molecules present in cells and tissue. The identities, concentrations, and fluxes of these substances are the final product of interactions between gene expression, protein expression, and the cellular environment. [1] [2] [3] [4] The metabolome thus defines a metabolic state as regulated by net interactions between gene and environment influences and provides information that can possibly bridge the gap between genotype and phenotype. Metabolic signatures for such disorders could result in the identification of biomarkers for disease, for disease progression, or for response to therapy. 1, 5 Major depressive disorder is associated with dysregulation of multiple neurotransmitter systems, including serotonergic and noradrenergic systems 6 and other neurotransmitters such as gamma-aminobutyric acid (GABA) 7, 8 and glutamic acid. 9, 10 Previously, we undertook a metabolomic analyses in a small sample of 9 depressed, 11 remitted, and 10 never-depressed older adults. 11 Metabolites that were altered in currently depressed patients compared with controls included GABA, glycerol, and several fatty acids, including oleate, stearate, and linoleate. Relative to currently depressed patients, remitted patients showed elevated concentrations of the ketone 3-hydroxybutanoic acid. As noted in a recent review, previous studies have found differences in n-3 and n-6 long-chain polyunsaturated fatty acids in depressed patients. 12 In the present study, we sought to expand our previous work, here in a more homogeneous sample of depressed patients enrolled in a pharmacological clinical trial and a similar group of non-depressed controls. We hypothesized that there would be differences between depressed and control groups in both lipid metabolism and in metabolic pathways related to neurotransmitter biosynthesis. Further, we expected to see differences in other metabolites, given the large numbers of compounds examined using this powerful technology.
Methods Participants
Depressed patients were participants in SADHART-CHF, an NIMH-sponsored, prospective, randomized, double-blind, placebo-controlled study that is designed to assess the safety and efficacy of sertraline in the treatment of heart failure patients with major depression (clinicaltrials.gov registry number NCT00078286). Study participants were primarily recruited from an academic center (Duke University Medical Center, the study's primary center) and 2 community hospitals and clinics (Durham Regional Hospital and Alamance Hospital), and their affiliated clinics. The study population consisted of patients who were at least 45 years of age, with diagnosis of chronic heart failure of any etiology. Eligible patients met the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition; DSM-IV) criteria for major depressive disorder and had a history of chronic systolic heart failure characterized by left ventricular ejection fraction <45% and New York Heart Association class II. They were not taking antidepressant medications at the beginning of the study.
Nondepressed control participants were recruited from Duke University Medical Center during the period when the above depressed patients were recruited. Controls met the same criteria for heart failure as the depressed participants.
Recruitment
Depressed participants. After initial, signed consent, patients with heart failure from the primary recruiting site (Duke University Medical Center) were screened for depressive symptoms, using the Beck Depression Inventory Scale (BDI). 13 Patients whose BDI scores were equal to or greater than 10 were given a second consent form to sign followed by the Diagnostic Interview Schedule (DIS), a structured psychiatric interview to assess MDD. Patients recruited from the satellite sites (Community hospitals and their clinics) were approached directly for participation in the trial prior to formal BDI screening. Depressed patients also consented to provide a blood sample for future laboratory analyses.
Nondepressed control participants. After initial, signed consent, patients with heart failure from the primary recruiting site (Duke University Medical Center) were screened for depressive symptoms, using the BDI. Patients whose BDI scores were less than 10 were given a second consent form to sign followed by the DIS, a structured psychiatric interview to assess MDD. Informed consent was obtained from each patient to examine their medical records for evidence of current or past depression diagnosis or current use of antidepressant medication. Individuals were excluded from the control group if they screened positive for any psychiatric disorder, were currently using antidepressant medication, or had current or past history of depression documented on their chart. Participants who met the control group criteria also provided written informed consent to obtain a blood sample for metabolomic analysis.
Blood Samples
Sample collection. We obtained blood samples from 40 currently depressed individuals and 40 nondepressed control participants. Samples were collected using a Vacutainer system (Ref# 367983) containing clot activator and gel serum separator and were centrifuged using a Sorvall Model RT 7 Plus Centrifuge at a g force of 1864 (3000 rpm for 10 minutes at a fixed angle of 34 ). The resulting plasma was aliquoted in cryogenic vial tubes (Fisher Scientific microtube 2 mL Catalog#: NC9739217) and frozen at -80 C. Of note, 21 of the controls had blood drawn using Vacutainer tubes (Ref# 362788) containing the chelating agent ethylenediaminetetraacetic acid (EDTA). Once all samples were collected, the tubes were marked with a unique number to blind them and were sent to Metabolon, Inc (Durham, North Carolina), where they were inventoried, immediately stored at -80 C, and then extracted using a proprietary solvent extraction method. None of the samples were previously frozen or thawed.
Sample preparation. At the time of analysis, samples were thawed and extracts prepared according to Metabolon's standard protocol, 14 which is designed to remove protein and dislodge small molecules bound to protein or physically trapped in the precipitated protein matrix. All aliquots and remaining samples were refrozen until the time of analysis. Extracts were then split for analysis on the gas chromatography (GC) and liquid chromatography (LC) platforms.
Data collection. Data were collected over a 4-day platform run with samples randomly distributed and balanced for depressed and control groups across each platform day. Also included were 24 technical replicates of process standard samples created from a homogeneous pool containing a mixture of human plasma samples (''MTRX''). The MTRX samples were used to monitor process variation and were treated independently throughout the process as if they were study samples. All process samples (MTRX, GROBs-a mixture of organic components used to assess GC column performance, process blanks, etc) were spaced evenly among the injections for each day and all experimental samples were randomly distributed throughout each day's run.
Data normalization and imputation. Data for each individual compound were normalized by calculating the median values for each run. This minimizes any interday instrument gain drift but does not interfere with intraday sample variability. For a given metabolite, missing values were assumed to be below the limit of detection and were imputed with the observed minimum after the normalization step.
Statistical Analysis
Welch's 2 sample t test and an analysis of covariance (ANCOVA) were used to analyze the data. The statistical analyses were performed on (natural) log-transformed data to account for increases in data variance that occur as the level of response is increased. T-test comparisons were calculated using the program ''R'' from the Free Software Foundation, Inc (available at http://www.r-project.org). Analysis of covariance was calculated using JMP version 8 (SAS Institute, Inc, Cary, North Carolina). Analyses of covariance were used to account for additional variable in the data including participant's age, statin use, and ejection fraction (EF).
As mentioned earlier, this data set consisted of 2 sets of control samples, 19 collected in tubes with clot activator and gel for plasma separation and 21 with tubes containing EDTA. Conversely, plasma samples isolated from the depressed participants were collected with only the clot activator and gel for plasma separation and, therefore, did not contain EDTA. For the statistical analysis of this data, we initially identified biochemicals that were significantly different within the control group, based on the presence or absence of EDTA. Then, for biochemicals with a significant EDTA difference within the control group, we proceeded with the 19 non-EDTA samples in subsequent analyses with the depressed group. For those biochemicals without a significant EDTA difference within the control group, we used all 40 control group participants in comparison with the depressed group. Random forest classification was used to classify participants. 15 Random forests are based on a consensus of a large number of decision trees that split the data into groups based on the biochemicals that provide the best separation between groups. The error rate from the random forest will give an estimate of how well one can predict new data. Random forest classification results were obtained with the use of the randomForest package in R. 16 Two parameters were evaluated when considering statistical significance, namely the P and the q values. 17 We used a P value less than .05 for significance coupled with a q value (describing the false discovery rate, FDR) 18 of less than .10 as an indication of high confidence in a result. The q values estimate cumulative FDR in the context of multiple tests.
Results
Plasma samples were obtained from 40 depressed and 40 control participants with heart failure (see Table 1 ). Depressed participants were younger than controls (58.5 and 66.4 years of age, respectively) but the 2 groups had similar ratios based on sex (about one-quarter female) and race (55% Caucasian). Clinically, the presence of ischemic heart disease was similar between depressed and control participants. Control participants had lower ejection fractions, while depressed participants had higher use of statin drugs.
Metabolomic analysis of the plasma samples obtained from the study population identified 205 known and 218 unknown biochemicals. In the comparison between the depressed and control group, 154 biochemicals were identified that showed statistically significant between-group differences (ie, P < .05 and q < .10). Of the 154 statistically significant biochemicals identified, there were, respectively, 68 and 86 biochemicals that showed fold-increased and fold-decreased concentrations within the depressed participants when compared with the control participants. However, when we limited our analysis to only those samples that were collected without EDTA, the comparisons identified 63 significantly different biochemicals: 40 with increased concentrations and 23 with decreased concentrations within depressed participants compared with their control counterparts.
Depressed Versus Control Comparisons
The initial set of comparisons performed for this study was for the purpose of initially identifying defining metabolites and pathways that are differently regulated in depression. With this goal in mind, numerous differences were initially identified between the depressed and control groups. These differences, detailed below, included biochemicals associated with amino acid metabolism and lipid metabolism.
As shown in Table 2 and Figure 1 , concentrations of several amino acids were found to differ significantly between depressed and control groups. Within this study, phenylalanine, aspartate acid, and serine were among the amino acids that were significantly elevated in depressed participants compared with controls. In addition, levels of g-glutamyl amino acids (g-glutamylleucine and g-glutamylglutamine) were found to be significantly elevated in depressed participants in comparison to control participants. However, 3-methyl-2-oxobutyrate, 3-methyl-2-oxovalerate, and 4-methyl-2-oxopentanoate, which are associated with valine, leucine, and isoleucine metabolism, were not found to be significantly altered in depressed participants.
For analyses related to lipid metabolism we examined concentrations of ketone bodies and dicarboxylic acids (DCAs; see Table 2 ). There were reduced levels of the ketone body 3-hydroxybutyrate in depressed versus control participants. A number of DCAs were observed to be elevated in depressed participants in relation to controls. These include an increase in the levels of azelate, suberate, sebacate, and 3-hydroxysebacate. As described below, several DCAs were identified through the random forest analysis as some of the most important biochemicals in the discrimination between depressed and nondepressed participants from this study. We then performed a series of ANCOVA analyses to examine effects of age, statin use, and ejection fraction. Compounds that were identified as having a significant age effect (P < .05 and q < .1) were limited to glutamate, hypoxanthine, xanthine, and trigonelline. Further analysis indicated that while there was a significant age effect with the above-mentioned compounds, there were no significant effect detected with either statin use or ejection fraction with any of the compounds detected within this study (P < .05 and q < .1).
In other analyses, we examined the effects of severity of heart failure (as measured by New York Heart Association classification) and of severity of depression (as measured by the BDI). After accounting for group differences (depressed vs no depression), there was no significant effect of heart failure severity. We did find a positive association (using Pearson correlation) for BDI score and several compounds, obtaining similar results as the previous analysis of depressed versus no depression.
Random Forest Classification
We used the entire metabolite dataset derived from plasma without EDTA for Random Forest analysis to classify depressed and nondepressed participants in this study. The confusion matrix within Figure 2 shows that 28 of the depressed participants were correctly classified as depressed, while 12 were misclassified as belonging to the control group. Of the 19 control group participants without EDTA, 15 were correctly classified as nondepressed participants while only 4 were incorrectly classified as belonging to the depressed group. From Figure 2 , there appear to be 7 biochemicals that are particularly important in differentiating the depressed participants from the control participants: unnamed biochemical X-4807, azelate, aspartate, X-11805, 3-hydroxysebacate, sebacate, and aspartylphenylalanine. Overall, 43 of the 59 plasma samples from groups B and C without EDTA were correctly classified, which resulted in a predictive accuracy of 43/59 ¼ 72.8%. The accuracy rate for discriminating depressed and nondepressed participants based on plasma samples was much higher than random chance (50%). It is interesting to note that 3 of the top biochemicals (azelate, 3-hydroxysebacate and sebacate) that contributed to the discrimination of depressed from nondepressed participants are DCAs associated with o-oxidation of fatty acids. These DCAs were found to be elevated in the depressed participants in relation to controls and are a possible indication of increased o-oxidation fatty acid metabolism. 19 Aspartate, as mentioned earlier, is an important neurotransmitter and was also very effective in discriminating between depressed and control participants.
Comment
The major findings of this metabolomic study are that we were able to identify differences in concentrations of several metabolites between depressed and nondepressed heart failure patients. Significant differences were found in key metabolic pathways, including amino acid metabolism and lipid metabolism. These findings build on a previous report by our group that identified between-group differences in several fatty acids, glycerol, and g-aminobutyric acid. 11 Several amino acids play an important role as neurotransmitters and studies have shown that major depression may be accompanied by alteration in serum, cerebrospinal fluid, or brain concentrations of many excitatory amino acids. 20 Glutamate and aspartate, 2 amino acids detected in this study, are considered to be the main excitatory amino acids in the central nervous system. 20, 21 Additionally, glutamate, aspartate, and serine play an important role with N-methyl D-aspartate (NMDA) receptors. N-methyl D-aspartate receptors are nonspecific cation channel receptors that act by mediating fast-synaptic transmission in the brain and are fundamental to memory and behavior. 22 Activation of the NMDA receptor can be initiated by the binding of the amino acid glutamate and aspartate. N-methyl D-aspartate receptors also require the additional binding of glycine or serine as a co-agonist for functional opening of the ion channel. Within this study, aspartate and serine were significantly elevated in depressed participants when compared with controls. Glutamate was initially identified as having a significantly elevated level within depressed participants; however, ANCOVA analysis later indicated that there was a significant age effect associated with glutamate. It should be noted that once accounting for age, the group effect was no longer significant for glutamate. There were other metabolites with a significant age effect, but the group effects remained significant. Several studies have identified elevated levels of glutamate and aspartate in serum samples from depressed participants in relation to nondepressed controls. 20, 21, 23 It has been suggested that brain concentration of these amino acids that exceed those normally found in the synaptic space can cause selective neuronal loss and may be involved in a variety of chronic neurological disorders. 24 Higher levels of the branched-chain amino acids (BCAA) leucine and isoleucine were also detected within the depressed participants in relation to the control group. Branched-chain amino acids are involved with systemic stress responses, they are regulators of protein synthesis and degradation, and they serve as key precursors for glutamine and alanine synthesis. 25 In particular, leucine plays a key role in several key brain metabolic functions, including serving as a precursor of fuel molecules, a-ketoisocaproate and ketone bodies, and as a regulator of the activity of some enzymes important for brain energy metabolism. 26 Phenylalanine is an essential amino acid and serves as a precursor for the amino acid tyrosine as well as for catecholamines in the body (tyramine, dopamine, epinephrine, and norepinephrine). In this study, the levels of phenylalanine were found to be slightly but significantly higher in depressed participants in relation to controls. It is not clear why this is the case. There may be dietary differences, differential absorption from the gastrointestinal tract, or other factors that would elevate levels in depressed participants or lower them in controls.
We also examined the data for indicators of oxidative stress in association with depression. Glutathione (GSH) is a tripeptide (L-g-glutamyl-L-cysteinyl-glycine) that is synthesized in the cytosol from the precursor amino acids glutamate, cysteine and glycine. Glutathione is the most abundant redox molecule and is critical in maintaining redox status in cells. 27 It also plays a key role in the detoxification of reactive oxygen species, reactive nitrogen species, and xenobiotic compounds in cells. However, glutathione (reduced or oxidized) was not detected in samples for this study, and pyroglutamate (5-oxoproline), which is also an indication of glutathione biosynthesis flux and oxidative stress, failed to show any significant difference between depressed and nondepressed participants. These results suggest that there was no increase in oxidative stress among the depressed participants.
Although the primary route of fatty acid metabolism is via b-oxidation, other metabolic pathways are known to contribute to fatty acid metabolism. For example, o-oxidation of fatty acids is known to occur in liver microsomes through an nicotinamide adenine dinucleotide phosphate (NADPH)-and cytochrome P450-dependent process by which the omega carbon of a fatty acid is oxidized to an alcohol and then to a carboxylic acid, thereby generating a DCA. Dicarboxylic acids produced by o-oxidation can be transported back into the mitochondria or to peroxisomes for b-oxidation. Dicarboxylic acids are produced when there is a defect in fatty acid oxidation or when mitochondrial b-oxidation is overwhelmed. 28, 29 A number of DCAs were observed to be elevated in depressed participants in relation to controls. These include an increase in the levels of azelate, suberate, sebacate, and 3-hydroxysebacate. Several DCAs were also identified through the random forest analysis as some of the most important biochemicals in the discrimination between depressed and nondepressed participants from this study. With regard to other fatty acids, we found depressed heart failure patients had lower concentrations of fatty acids such as docosahexaenoic acid (DHA) compared with nondepressed patients, but the differences were not different statistically. This may be due to the relatively small sample size in the study.
In addition to this, we also found decreased level of the ketone body 3-hydroxybutyrate in depressed participants in comparison with controls. Ketone bodies are generated from acetyl-CoA formed during b-oxidation of fatty acids and can be used as fuel for the brain and central nervous system. In a normal situation, lipids undergo b-oxidation, eventually resulting in the accumulation of acetyl-CoA that may then enter the TCA cycle for energy production. However, if the levels of acetyl-CoA reach a point such that they exceed the requirements of the TCA cycle, then the excess is directed toward the formation of ketone bodies such as 3-hydroxybutyrate. It is interesting to note from this study that while there was a reduction in the level of 3-hydroxybutyrate, there also was an increase in the levels of several DCAs. This suggests that in the depressed participants examined for this study, metabolism of fatty acids may have been a shift away from b-oxidation and redirected toward o-oxidation. These data are further supported by the findings from the random forest analysis that several of the DCAs were actually the best predictors between the depressed and nondepressed participants. We demonstrated the importance of both amino acids and DCAs in differentiating between the depressed and nondepressed groups, with a predictive accuracy of 78.2%. However, at this time, the relationship of increased DCA formation through o-oxidation and depression is unclear. As others have noted, in humans, medium-chain DCAs, for example, adipic (C6), suberic (C8), sebacic (C10), and dodecanedioic (C12) acids, derive from the b-oxidation of longer-chain DCAs. Long-chain DCAs, in turn, are formed from the correspondent fatty acids by o-oxidation in the microsomial membranes or are consumed with a diet rich in vegetables. 30 This metabolomic study advances our understanding of biochemical processes involved with depression. Yet, the study is not without limitations. The sample size, although relatively small, is comparable to other studies that were successful in mapping signatures for neuropsychiatric conditions, 31, 32 other medical conditions, [33] [34] [35] and individuals drugs. 5, 36 Absence of a control group without heart failure might also be seen as a limitation. Depressed participants in this study were recruited as part of an antidepressant trial and as such they may differ in some respects from the larger population of depressed patients with systolic dysfunction and class II or higher heart failure. Another potential limitation is lack of anthropomorphic data, for example, height and weight for determination of body mass index (BMI). Our findings related to fatty acids and depression raise the possibility that metabolic syndrome may be important in depressed heart failure patients, and data related to BMI would have been helpful in this regard.
The fact that about half of the control samples contained EDTA initially posed a problem, but we feel our approach adequately dealt with this issue. Finally, we chose to focus on a more medically homogeneous group of patients with heart failure, so it is not clear whether our findings are generalizable to other depressed adults. Furthermore, future studies will need to examine heart failure-related variables (eg, ischemic versus nonischemic heart failure, use of statins and other medications), comorbid medical conditions, and cardiac outcomes.
In summary, in this metabolomic analysis of patients with heart failure, we found that the concentrations of several biochemical compounds differed between depressed and control participants. Numerous amino acid neurotransmitters were found to be elevated in depressed participants in comparison to nondepressed control participants. Depressed participants had reduced levels of ketone body formation along with increased levels of DCA formation, which suggested reduced b-oxidation and enhanced o-oxidation of fatty acids in depressed participants. Inositol levels were also reduced in the depressed participants in relation to controls, a finding consistent with previous studies. Finally, we showed that Random forest classification analysis was able to distinguish between depressed and nondepressed samples with a 72.8% success rate. Our study focused on heart failure patients, and it is unclear whether presence of this medical condition in all participants would have affected the results among depressed and nondepressed groups. Future studies should attempt to replicate these findings in populations with larger sample sizes and with different medical comorbidities. In addition, other markers should be included, such as those related to inflammation or neurohormonal activation, as both have been linked to depression and heart failure. 37, 38 Metabolon, Inc. WJ and CMO report no conflict of interest related to this manuscript. DCS had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
